Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Noonan Syndrome 1Neoplasms 1Melanoma 1Lung Neoplasms 1Intestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1EGFR-mutant Non-small Cell Lung Cancer 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Docetaxel 4pembrolizumab 2Carboplatin 2tislelizumab 1nazartinib 1lenvatinib 1cemiplimab 1aflutinib 1abivertinib 1Rosuvastatin Calcium 1Platinum Compounds 1Pemetrexed 1Nivolumab 1Midazolam 1Gefitinib 1Food 1Esomeprazole 1Dabigatran 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Non-small Cell Lung Cancer × nazartinib × Clear all
NCT02108964 2024-12-11

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Novartis

Phase 1/2 Completed
225 enrolled 31 charts
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡